Oxurion NV - Company Profile
Powered by 
All the sales intelligence you need on Oxurion NV in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Oxurion NV fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Oxurion NV.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Oxurion NV (Oxurion) is a biopharmaceutical company. It is dedicated to developing innovative therapies for retinal disorders, particularly Geographic Atrophy (GA). The company employs a unique approach by utilizing a CRISPR-based target discovery platform to identify cytoprotective pathways that are essential for halting GA progression. Oxurion’s mission is to prevent blindness and enhance vision for patients worldwide, addressing critical unmet medical needs in ophthalmology. The company operates through its two wholly owned subsidiaries, ThromboGenics Inc. and Oncurious NV. Its research and development (R&D) team is intensifying preclinical trial efforts through advanced gene modulation techniques and genome-wide screening, all conducted at the Bio-Incubator facility in Leuven. Oxurion is headquartered in Leuven, Belgium.
Headquarters
Belgium
Address
Gaston Geenslaan 1, Leuven, 3001
Website
www.oxurion.com
Telephone
32 16 751310
No of Employees
26
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
OXUR (EBR)
Revenue (2024)
$626,200
18400%
(2024 vs 2023)
EPS
XYZ
Net Income (2023)
XYZ
-3232.8%
(2023 vs 2022)
Market Cap*
$380,000
Net Profit Margin (2024)
XYZ
-116.9%
(2023 vs 2022)
* As of and is in US$
Oxurion NV premium industry data and analytics
Products and Services
| Services |
|---|
| Research and Development of Therapies for Geographic Atrophy |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Plans/Strategy | In July, the company announced its plans to acquire an 80% stake in a CRO (Contract Research Organisation) in stem cell production. |
| 2021 | Financing Agreements | In April, the company announced to secure EUR30 million investment from Negma Group. |
| 2020 | Contracts/Agreements | In March, the company has entered into global license agreement with Inceptua Group for the commercialization of Jetrea. |
Competitor Comparison
| Key Parameters | Oxurion NV | ICON Plc | Oxular Ltd | Amakem NV | Azad Pharma AG |
|---|---|---|---|---|---|
| Headquarters | Belgium | Ireland | United Kingdom | Belgium | Switzerland |
| City | Leuven | Dublin | Oxford | Diepenbeek | Toffen |
| State/Province | - | Dublin | England | Limbourg | Bern |
| No. of Employees | 26 | 39,800 | 5 | - | - |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Pascal Ghoson | Chief Executive Officer; Chief Financial Officer; Director | Executive Board | 2023 | - |
| Andy De Deene, M.D. | Chief Development Officer | Senior Management | - | - |
| Charles Paris de Bollardiere | Chairman | Non Executive Board | 2023 | - |
| Philippe Barbeaux | Chief Scientific Officer | Senior Management | - | - |
| James Hartmann | Director | Non Executive Board | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer